SPOTLIGHT: Novartis touts new MS data
Researchers at Novartis say that after three years of therapy in an ongoing Phase II study, the oral FTY720 demonstrated positive results for patients with multiple sclerosis. Data demonstrate that 73 percent of patients who began the study on FTY720 5 mg remained free from relapses after three years. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
